BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline?

Key Points BMO Capital Markets downgraded BioNTech and lowered its price target for the stock. The move came after BioNTech reduced its 2027 guidance and experienced a clinical setback. However, BioNTech's pipeline still includes over 25 oncology candidates in Phase 2 and Phase 3 trials. 10 stocks we like better than BioNTech Se › BMO (NYSE: BMO) Capital Markets has been quite bullish about BioNTech SE (NASDAQ: BNTX) this year. However, that's no longer the case. On Sept. 8, 2026, BioNTech's shares dipped after BMO downgraded the biotech stock from an "outperform" rating to a "market perform" rating. BMO also lowered its 12-month price target for BioNTech from $128 to $105. Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger.